GlassScriptPhysician profile
Daniel C Hobbs
NPI 1922418185
$896.31
in general payments reported to CMS, 2019-2025
15 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2021: $68.20 · 2022: $130 · 2023: $323 · 2024: $98.98 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $226.43 | 2019-2024 | Watchman Access System |
| Abiomed | $141.80 | 2023 | Impella |
| Pfizer INC. | $95.55 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $84.82 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $63.59 | 2022-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.45 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.85 | 2025 | |
| Alnylam Pharmaceuticals INC. | $30.18 | 2025 | Onpattro |
| Becton, Dickinson and Company | $28.46 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.93 | 2023-2024 | Xarelto |
| Amgen INC. | $26.41 | 2022 | |
| Novo Nordisk INC | $23.11 | 2024 | Ozempic |
| Philips North America LLC | $20.02 | 2022 | |
| Bridgebio Pharma, INC. | $14.85 | 2025 | Attruby |
| Cvrx, INC. | $12.86 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hobbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.